Dechra Pharmaceuticals

What Dechra Pharmaceuticals does

Dechra Pharmaceuticals is an international veterinary pharmaceuticals company that develops, manufactures, and distributes specialty pharmaceutical products exclusively for veterinary professionals. The company's portfolio is organized around key therapeutic areas for companion animals (dogs, cats, and horses), including endocrinology (CosACTHen®, Zygolide®), anti-infectives (Solovecin™, Emeprev™), dental care (VETRADENT®), and pain management. Recent R&D has yielded several first-in-class FDA approvals, including the only cosyntropin indicated for canine patients and the first bioequivalent generic pergolide for equine Cushing's disease, and the company is expanding into veterinary biologics following the 2024 acquisition of Invetx, a monoclonal antibody platform.

Dechra operates a B2B go-to-market model with no direct-to-consumer sales; products are sold through own sales offices in 27 markets and through a curated network of authorized distribution partners in an additional 87 countries, giving it coverage in 114 markets. The company runs seven manufacturing sites globally, supports customers through the Dechra Academy continuing education platform, and pursues a sustainability agenda that has delivered a 40% reduction in Scope 1 and 2 emissions five years ahead of its 2030 target. In June 2025 it divested its Avishield poultry vaccines business to Vaxxinova to refocus on companion animal specialty therapeutics.

In 2024 Dechra was taken private by EQT Group in a £4.5 billion transaction co-invested by Abu Dhabi Investment Authority (ADIA), and in 2026 it relocated its global headquarters from Northwich, England to Boston, Massachusetts, consolidating its North American footprint. The company reported revenue of approximately $967 million in 2023 (most recent disclosed period in source data), employs roughly 2,760 people globally, and has been actively reshaping its senior leadership team and product pipeline through targeted acquisitions (Invetx, Piedmont Animal Health, Med Pharmex) and a steady cadence of regulatory approvals.

Name

Dechra Pharmaceuticals

Legal name

Dechra Pharmaceuticals Limited

Website

https://dechra.com

Company type

Private

Founded year

1997

Operating status

Operating

Headcount range

501–1,000 employees

Short description

Dechra Pharmaceuticals is a global veterinary pharmaceuticals company that develops, manufactures, and distributes specialty drugs exclusively for veterinary professionals across 114 countries, with focus on endocrinology, anti-infectives, dental, and pain management for companion animals.

Ownership category

akta.pro rank

Product category

Veterinary Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412), Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Oncology & Specialty Therapeutics (HLAMAEAJ)

akta.pro secondary industries

Endocrinology & Metabolic Drugs (e.g., Diabetes, Thyroid) (HLAMAEAG), Antimicrobials & Anti-infectives (HLAMAEAE), Biologics & Immunotherapies (Non-vaccine) (HLAMAEAK)

Keywords

• Veterinary pharmaceuticals
• Animal health therapeutics
• Companion animal medicines
• Equine endocrinology drugs
• Veterinary biologics

Headquarters

HQ city

Northwich

HQ country

United Kingdom

HQ region

Europe

Offices7 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Operations, Personnel, Technology or R&D, Marketing or Sales

Revenue model

1. Veterinary Pharmaceutical Products: Development, manufacturing, and sale of veterinary pharmaceuticals exclusively for veterinarians worldwide, including specialty care products for companion animals
2. Product Licensing and Distribution: Licensing agreements for product distribution such as Intervacc's Strangvac equine strangles vaccine, and sale of product portfolios such as Avishield poultry vaccines

Go-to-market motion2 records

Distribution channels4 records

Marketing channels6 records

Core offering

Dechra Pharmaceuticals develops, manufactures, and sells specialty veterinary pharmaceutical products exclusively for licensed veterinary professionals worldwide. Its portfolio spans endocrinology, anti-infectives, antiemetics, dental care, dermatology, and pain management for companion animals (dogs, cats) and horses, supplemented by distributed vaccines and recently acquired monoclonal antibody biologics.

Product overview

Dechra Pharmaceuticals is an international veterinary pharmaceuticals and related products business that operates as a single unified product portfolio serving veterinary professionals. The company provides high-quality pharmaceutical products exclusively for veterinarians worldwide, organized around therapeutic areas including endocrinology (CosACTHen®, Zygolide®), anti-infectives (Solovecin™), antiemetics (Emeprev™), dental care (VETRADENT®), and distributed vaccines (Strangvac). Dechra also acquired Invetx to expand into novel monoclonal antibody therapeutics for companion animals. The products are complemented by Dechra Academy for professional training and are distributed through direct sales channels in 27 markets plus distribution partners in 87 additional countries.

Differentiator

Problem solved

Functional benefit

Brands

• VETRADENT: Dental wipes for dogs
• Solovecin
• CosACTHen
• Zygolide
• Emeprev
• Avishield

Products and services

• CosACTHen (cosyntropin injection) FDA-approved cosyntropin injection for canine ACTH stimulation testing to evaluate adrenal function, the first and only cosyntropin specifically indicated for dogs. Used by veterinarians to diagnose, confirm, and monitor Cushing's Disease and Addison's Disease.
• Zygolide (pergolide tablets) FDA-approved bioequivalent generic pergolide tablets for controlling clinical signs associated with Pituitary Pars Intermedia Dysfunction (Equine Cushing's Disease) in horses. Available through veterinarians and major online pharmacies.
• Emeprev (maropitant citrate) Injectable Solution FDA-approved bioequivalent maropitant citrate injectable solution for the treatment of vomiting in dogs and cats. Preservative-free formulation that does not require refrigeration.
• Solovecin (cefovecin sodium) In-clinic injectable antibiotic (cefovecin sodium) for skin infections in dogs and cats. Provides a full course of therapy in a single injection, improving treatment compliance.
• VETRADENT Dental Wipes for Dogs Dental hygiene wipes for dogs that have been awarded the Veterinary Oral Health Council (VOHC) Seal of Acceptance for proven tartar control performance.
• Strangvac (equine strangles vaccine) Equine strangles vaccine distributed by Dechra in the UK, Spain, Portugal, Slovenia, and Finland under a distribution agreement with Intervacc. Used by equine veterinarians for prevention of strangles (Streptococcus equi).
• Invetx (novel monoclonal antibody therapeutics for pets) Biotechnology platform developing protein-based therapeutics and novel monoclonal antibody products for companion animals, acquired for up to $520 million in July 2024. Expands Dechra into veterinary biologics and specialty medicine.
• Piedmont Animal Health companion animal products Novel product development pipeline for the companion animal market acquired in 2022 to enhance Dechra's therapeutic areas. Products from the acquisition are expected to launch in 2024 and 2025.

Quantifiable outcome

• 98% of respondents agreed interactions with animals can have positive impact on human health, with 93% believing they could create stronger communities (Boston survey n=200)
• +2 more outcomes

Named customers4 records

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Nine partnerships are on record, tiered core and minor.

• Pet PartnerscoreGTM or Marketing Partner · 25 June 2026$50,000 investment to expand animal therapy programs across Boston including education, evaluation, certification and insurance for volunteers and therapy animals. Strategic partnership rooted in elevating human-animal bond and pet wellbeing in communities.
• Boston Police FoundationminorGTM or Marketing Partner · 25 June 2026$10,000 donation to support Boston Police Department's Comfort Dog Program community engagement initiatives, supporting positive interactions through Copper the comfort dog to foster trust and connection between law enforcement and communities.
• HABRIcoreStrategic or Co-development Partner · 7 November 2025Human-Animal Bond Certified Company partnership providing veterinary professionals with education on scientifically-documented benefits of human-animal bond. Dechra colleagues and customers access certification training through NAVC's Vetfolio platform.
• NAVCcoreStrategic or Co-development Partner · 7 November 2025Partnership with North American Veterinary Community for Human-Animal Bond Certification program delivery through Vetfolio online platform, making continuing education accessible for veterinarians.
• IntervacccoreChannel Partner/ Reseller/ Distributor · 13 October 2025Distribution agreement for Intervacc's equine strangles vaccine Strangvac extended by two years starting April 2026. Dechra launched vaccine in UK, Spain, Portugal, and Slovenia while Intervacc manages Scandinavia distribution. Dechra continues expanding distribution across European markets.
• VaxxinovacoreStrategic or Co-development Partner · 17 June 2025Sale of Avishield poultry vaccines portfolio including eight products marketed in 29 countries. R&D team of 24 people in Zagreb transfers to Vaxxinova. Dechra manufactures and distributes products for two-year transitional period while technical transfer occurs. Dechra leasing Zagreb R&D facility for three years.
• Akston BiosciencesminorStrategic or Co-development Partner · 30 July 2024Dechra purchased veterinary insulin programs from Akston Biosciences as part of expanding portfolio in veterinary therapeutics for companion animals.
• InvetxcoreStrategic or Co-development Partner · 18 July 2024Acquisition of Invetx, Boston-based biotech specializing in protein-based animal therapeutics and monoclonal antibody products for pets. Deal valued at up to $520 million, enabling expansion in veterinary biologics and specialty medicine.
• Piedmont Animal HealthcoreStrategic or Co-development Partner · 20 July 2022Acquisition agreement for Piedmont Animal Health specializing in novel product development for companion animal market. Products expected to launch in 2024 and 2025, enhancing Dechra's product pipeline and key therapeutic areas.

Scale indicators8 records

Recent moves2 records

Direct peers

• Vetoquinol: Independent French veterinary pharmaceutical company serving companion and livestock markets with focus on specialty therapeutics. Direct peer in companion animal pharmaceuticals with comparable international distribution model.
• Phibro Animal Health: Animal health and mineral nutrition company offering pharmaceuticals and vaccines for livestock and companion animals. Comparable as a mid-cap specialty animal health player with global distribution, though more weighted to production animal markets.
• Virbac: Independent French animal health company focused on pharmaceuticals, vaccines, and diagnostics for companion and farm animals. Direct mid-sized competitor to Dechra in specialty veterinary pharmaceuticals, with similar global footprint and similar emphasis on companion animal health.
• Ceva Santé Animale: Global veterinary pharmaceutical company headquartered in France, with companion animal and livestock products. Direct competitor to Dechra, comparable in scale and product categories, especially in companion animal therapeutics.
• Norbrook Laboratories: Privately held veterinary pharmaceutical company headquartered in Northern Ireland, manufacturing companion and livestock animal health products. Closely comparable mid-sized veterinary pharma peer with similar proprietary anti-infective and parasiticide portfolio.

Broad incumbents

• Elanco Animal Health: Major publicly traded animal health company with companion animal and livestock pharmaceuticals, vaccines, and parasiticides. Competes with Dechra in specialty pharma categories but at much larger scale and broader portfolio.
• Zoetis: World's largest animal health company selling pharmaceuticals, vaccines, diagnostics, and biologics across companion and livestock species. Overlaps with Dechra across companion animal endocrinology, anti-infectives, and dermatology, but serves a vastly broader portfolio including livestock vaccines and diagnostics.
• Boehringer Ingelheim Animal Health: Animal health division of Boehringer Ingelheim, one of the largest veterinary pharma players with companion animal parasiticides, vaccines, and therapeutics. Overlaps Dechra in companion animal specialty pharmaceuticals with much greater scale and global reach.

Emerging players

• PetIQ: Animal health products and services company distributing pet medications, OTC, and veterinary wellness products through retail and veterinary channels. Indirect competitor on the companion animal channel side, particularly relevant given Dechra's pivot to deepen distribution to vet practices.

Others

• IDEXX Laboratories: Leader in veterinary diagnostics and software for companion animals. Not a direct pharma competitor but is a critical counterpart that drives practice-level economics and prescription behavior, and IDEXX's therapeutics and reference lab services partially overlap with Dechra's specialty positioning.

Market position

Strengths5 records

Weaknesses5 records

Key risks5 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/dechra-veterinary-products
• Xx.com/Dechra
• Facebookfacebook.com/about.php

Revenue estimate

Valuation estimate

Number of profiles

Profiles15 records

Subsidiaries3 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A14 records

Investments1 record

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Dechra Pharmaceuticals